Piper Jaffray Companies set a $17.00 target price on Impax Laboratories, Inc. (NASDAQ:IPXL) in a report issued on Thursday. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

IPXL has been the topic of a number of other reports. Canaccord Genuity set a $19.00 price objective on shares of Impax Laboratories and gave the company a hold rating in a research report on Wednesday. Vetr lowered shares of Impax Laboratories from a strong-buy rating to a strong sell rating and set a $10.55 target price on the stock. in a research report on Monday, May 1st. Cantor Fitzgerald set a $20.00 target price on shares of Impax Laboratories and gave the stock a buy rating in a research report on Wednesday. Deutsche Bank AG set a $21.00 target price on shares of Impax Laboratories and gave the stock a buy rating in a research report on Monday, July 17th. Finally, Zacks Investment Research lowered shares of Impax Laboratories from a hold rating to a strong sell rating in a research report on Monday, July 24th. Four investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $18.56.

Shares of Impax Laboratories (NASDAQ:IPXL) traded up 0.55% during mid-day trading on Thursday, reaching $18.30. 1,600,694 shares of the company were exchanged. The stock has a 50 day moving average price of $17.34 and a 200-day moving average price of $14.34. The stock’s market capitalization is $1.31 billion. Impax Laboratories has a 12 month low of $7.75 and a 12 month high of $27.29.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.04. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The firm had revenue of $202.08 million for the quarter, compared to analyst estimates of $195.62 million. During the same period last year, the firm posted $0.21 EPS. Impax Laboratories’s quarterly revenue was up 17.1% on a year-over-year basis. Analysts predict that Impax Laboratories will post $0.68 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Reiterates “$17.00” Price Target for Impax Laboratories, Inc. (NASDAQ:IPXL)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/13/piper-jaffray-companies-reiterates-17-00-price-target-for-impax-laboratories-inc-nasdaqipxl.html.

Several large investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its stake in Impax Laboratories by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 8,140 shares of the specialty pharmaceutical company’s stock valued at $102,000 after buying an additional 150 shares in the last quarter. Commerce Bank raised its stake in Impax Laboratories by 12.9% in the first quarter. Commerce Bank now owns 11,460 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 1,310 shares in the last quarter. Appleton Partners Inc. MA acquired a new stake in Impax Laboratories during the second quarter valued at approximately $191,000. Virtu KCG Holdings LLC acquired a new stake in Impax Laboratories during the second quarter valued at approximately $231,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Impax Laboratories by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock valued at $182,000 after buying an additional 171 shares in the last quarter. Institutional investors and hedge funds own 83.48% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.